ClinicalTrials.gg
CompletedNCT02260089Updated Oct 9, 2014

Telmisartan in Mild to Moderate Hypertensive Patients

A Phase 4 interventional study of Low dose of telmisartan and High dose of telmisartan in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-09.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
134
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
55th of 74
134 · median 381
Started
2000
with 10 others
Phase 4
26 of 122
none open now
Registered
116th of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 55th largest by enrollment of the 74 interventional ones that give a count, is one of 11 that started in 2000, is one of 26 in phase 4, and was the 116th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

To evaluate the efficacy and tolerability of telmisartan, given once a day to patients with mild to moderate hypertension, as well as to assess the 24-hour blood pressure profile with ABPM

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with blood pressure levels of 140/90 mm Hg or higher (confirmed on 2 consecutive visits), who were 18 years old and older, regardless of sex

Exclusion criteria

Exclusion Criteria:

  • Suspected or known diagnosis of arterial hypertension with a secondary cause
  • Women who were not using an effective method of , or who were pregnant, or breast-feeding
  • Systolic blood pressure > 200 mm Hg or diastolic blood pressure > 115 mm Hg
  • Laboratory test values two fold above the upper normal limit
  • Previous intolerance to angiotensin conversion enzyme inhibitors or angiotensin II blocker (AIIAR)
  • class III or IV heart failure
  • History of stroke in the 6 months prior to entry into the study
  • Uncontrolled type 2 diabetes mellitus, defined as fasting glucose levels > 140 mg/dL on 3 consecutive assessments
  • Patients who were included in another drug study in the past 30 days
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Low dose of telmisartan

    4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan

    Drug: Low dose of telmisartan · Drug: Placebo

  • Experimental
    High dose of telmisartan

    After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg

    Drug: High dose of telmisartan

Interventions

  • DrugLow dose of telmisartan
  • DrugHigh dose of telmisartan
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP)

    Blood pressure values were obtained 24 hours after the last dose (through values) at the office

    Time frame: Baseline, up to 12 weeks after start of treatment

Secondary outcomes

  1. Assessment of treatment response for SBP/DBP (in %)

    Response categories: * SBP \< 140 mm Hg or * DBP \< 90 mm Hg or * BP reduction ≥ 10 mm Hg

    Time frame: Baseline, up to 12 weeks after start of treatment

  2. Changes from baseline in blood pressure values

    Analysis performed for the ambulatory blood pressure monitoring (ABPM) - subgroup

    Time frame: Baseline, up to 12 weeks after start of treatment

  3. Number of patients with adverse events

    Time frame: Up to 16 weeks

  4. Number of patients with clinically significant changes in laboratory values

    Time frame: Up to 16 weeks

  5. Number of patients with clinically significant changes in ECG

    Time frame: Up to 16 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2000 and a primary completion of Jul 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2014
First posted
Oct 9, 2014
Start
Mar 2000
Primary completionActual
Jul 2002
Last update
Oct 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02260089
Responsible party
Sponsor
First posted
Oct 9, 2014
Start date
Mar 2000
Primary completion
Jul 2002
Last update
Oct 9, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion